Safety of Subcutaneous Administration of Rituximab during the First-Line Treatment of Patients with Non-Hodgkin Lymphoma: The MabRella Study

被引：2
|
作者：
Panizo, Carlos [1 ]
Bekadja, Mohamed Amine [2 ]
Meddeb, Balkis [3 ]
Mendoza, Maria Rigoroso [4 ]
Truman, Matt [5 ]
Smith, Rodney [4 ]
Barate, Claudia [6 ]
机构：
[1] Clin Univ Navarra, Pamplona, Spain
[2] Univ Hosp Estab, Oran, Algeria
[3] Aziza Othmana Univ Hosp, Tunis, Tunisia
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] F Hoffmann La Roche Ltd, Dee Why, Australia
[6] Univ Pisa, Pisa, Italy
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.2971.2971
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2971
引用
收藏
页数：5
相关论文
共 50 条
  • [31] A First in Non-Hodgkin Lymphoma Treatment
    Voelker, Rebecca
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 321 (01): : 23 - 23
  • [32] Efficacy and safety of rituximab plus low-dose oral fludarabine and cyclophosphamide as first-line treatment of elderly patients with indolent non-Hodgkin lymphomas
    Fabbri, Alberto
    Cencini, Emanuele
    Rigacci, Luigi
    Bartalucci, Giulia
    Puccini, Benedetta
    Dottori, Roberto
    Gozzetti, Alessandro
    Bosi, Alberto
    Bocchia, Monica
    LEUKEMIA & LYMPHOMA, 2014, 55 (04) : 781 - 785
  • [33] Interim results of a phase III study of bendamustine/rituximab versus R-CHOP as first-line therapy for patients with indolent non-Hodgkin lymphoma
    Jagannath, Sundar
    Cunningham, Sonia
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (01): : 13 - 14
  • [34] Rituximab combinations in the treatment of non-Hodgkin's lymphoma
    Leonard, John P.
    CANCER INVESTIGATION, 2007, 25 : 43 - 44
  • [35] Safety and Efficacy of Intrathecal Rituximab in Children with Non-Hodgkin Lymphoma: A Retrospective Study
    Xiong, X.
    Li, Y.
    Peng, X.
    Chuchu, F.
    Pingping, W.
    Wenjun, W.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S590 - S590
  • [36] COST-MINIMIZATION ANALYSIS OF RITUXIMAB SUBCUTANEOUS FORMULATION VERSUS INTRAVENOUS ADMINISTRATION OF RITUXIMAB FOR THE TREATMENT OF NON-HODGKIN'S LYMPHOMA IN THE REPUBLIC OF MACEDONIA
    Nikolov, O.
    Sterjev, Z.
    Dimovski, A.
    Kapedanovska-Nestorovska, A.
    Naumovska, Z.
    Grozdanova, A.
    Cevreska, L.
    Georgievski, B.
    Stojanovik, A.
    Karanfilski, O.
    Genadieva-Stavrik, S.
    Trajkova, S.
    Pivkova-Veljanovska, A.
    Sotirova, T.
    Pavkovic, M.
    Trpkovska-Terzieva, S.
    Amzai, G.
    Cadievski, L.
    Dukovski, D.
    Suturkova, L.
    HAEMATOLOGICA, 2017, 102 : 600 - 600
  • [37] Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice
    Becker, M.
    Tschechne, B.
    Reeb, M.
    Schwinger, U.
    Bruch, H. -R.
    Frank, M.
    Strassl, L.
    ANNALS OF HEMATOLOGY, 2015, 94 (09) : 1553 - 1558
  • [38] Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice
    M. Becker
    B. Tschechne
    M. Reeb
    U. Schwinger
    H.-R. Bruch
    M. Frank
    L. Straßl
    Annals of Hematology, 2015, 94 : 1553 - 1558
  • [39] First-line treatment of Hodgkin's lymphoma
    Klimm B.
    Engert A.
    Diehl V.
    Current Hematologic Malignancy Reports, 2006, 1 (1) : 51 - 59
  • [40] Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s LymphomaA NICE Single Technology Appraisal
    Janette Greenhalgh
    Adrian Bagust
    Angela Boland
    Michaela Blundell
    James Oyee
    Sophie Beale
    Yenal Dundar
    Juliet Hockenhull
    Chris Proudlove
    Patrick Chu
    PharmacoEconomics, 2013, 31 : 403 - 413
12345